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Abstract Studies on postoperative complications and survival in patients with pancreatic neuroendocrine tumors
(pNET) are sparse and randomized controlled trials are not available. We reviewed all studies on postoperative
complications and survival after resection of pNET. A systematic search was performed in the Cochrane Central
Register of Controlled Trials, MEDLINE and EMBASE from 2000–2013. Inclusion criteria were studies of resected
pNET, which described postoperative complications separately for each surgical procedure and/or 5-year survival
after resection. Prospective and retrospective studies were pooled separately and overall pooled if heterogeneity was
below 75 %. The random-effect model was used. Overall, 2643 studies were identified and after full-text analysis 62
studies were included. Pancreatic fistula (PF) rate of the prospective studies after tumor enucleation was 45 %; PF-
rates after distal pancreatectomy, pancreatoduodenectomy, or central pancreatectomy were, respectively, 14–14–
58 %. Delayed gastric emptying rates were, respectively, 5–5–18–16 %. Postoperative hemorrhage rates were,
respectively, 6–1–7–4 %. In-hospital mortality rates were, respectively, 3–4–6–4 %. The 5-year overall survival (OS)
and disease-specific survival (DSS) of resected pNET without synchronous resected liver metastases were, respec-
tively, 85–93 %. Heterogeneity between included studies on 5-year OS in patients with synchronous resected liver
metastases was too high to pool all studies. The 5-year DSS in patients with liver metastases was 80 %. Morbidity
after pancreatic resection for pNET was mainly caused by PF. Liver resection in patients with liver metastases seems
to have a positive effect on DSS. To reduce heterogeneity, ISGPS criteria and uniform patient groups should be used
in the analysis of postoperative outcome and survival.
Introduction
Given the rarity of pancreatic neuroendocrine tumors
(pNET), well-designed randomized controlled trials on
surgical treatment for pNET are not available [1–3]. Most
studies are cohort studies or case reports and therefore the
level of evidence in studies on surgical treatment of pNET
is limited to level III.
Studies on postoperative complications and in-hospital
mortality often describe pNET as part of a larger study
population. These studies include patients with pancreatic
ductal adenocarcinoma, intraductal papillary mucinous
neoplasm (IPMN), chronic pancreatitis, pancreatic adeno-
mas as well as pNET [4–6]. These diagnoses may influence
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the postoperative complication rate and operative mortal-
ity. It is well known that patients with pancreatitis have a
lower postoperative pancreatic fistula rate compared to
non-pancreatitis patients [7]. Furthermore, postoperative
complications after pancreatic surgery for pNET are
influenced by the type of surgery, such as pancreatoduo-
denectomy, distal pancreatectomy, central pancreatectomy,
or enucleation [8–11]. Studies analyzing postoperative
complications caused by the different surgical procedures
in patients with pNET are limited.
Survival of pNET patients is mainly affected by metas-
tasis found at the time of diagnosis. The overall 5-year sur-
vival of non-functional pNET in patients with distant
metastases (M1) is 43 % with a median survival of
23 months In contrast, patients with resected functional
pNET without metastases (M0) have a survival rate of
90–100 % [2, 3]. Survival is often presented by tumor stages
but different staging systems are used, e.g., American Joint
Committee on Cancer (AJCC) staging or European Neuro
Endocrine Tumor Society (ENETS) staging system [12, 13].
Another difficulty in analyzing survival of patients with
pNET after resection is the inclusion of non-hereditary and
hereditary patients in the same cohort. Survival outcome of
patients Multiple Endocrine Neoplasia type 1 (MEN-1) or
Von Hippel–Lindau (VHL) disease may be influenced since
these tumors are often early diagnosed and indication for the
surgical treatment can be different [3].
Considering the limitations of most studies as summa-
rized, the aim of this study was to systematic review all
studies on postoperative complications and 5-year survival
in patients with resected pNET.
Methods
Search methods and identification of studies
All types of study, including cohort, case-control or case
series and languages, were included. Inclusion period
ranged from January 2000 till December 2013. Studies
before 2000 were not included. In 2000, the WHO classi-
fication was introduced and clearly defined the phenotypes
of NETs and their clinicopathological conditions. In order
to reduce ambiguities and heterogeneity on pathological
origin from the included studies, the time for inclusion was
from 2000 to 2013 [14]. The Cochrane Central Register of
Controlled trials (CENTRAL) in the Cochrane Library,
MEDLINE and EMBASE were searched for studies. Also
the references of the identified studies were searched to
identify suitable studies.
The search strategy was supervised by the local librarian
and the query terms ‘‘neuroendocrine tumor’’, ‘‘carcinoid’’,
‘‘pancreas’’, ‘‘foregut’’, ‘‘pNET’’, ‘‘GEP-NET’’, ‘‘pancre-
atoduodenectomy’’, ‘‘enucleation’’, ‘‘pancreatectomy’’,
‘‘complications’’, ‘‘fistula’’, ‘‘bleeding’’, ‘‘delayed gastric
emptying’’, ‘‘survival’’ or every possible variants of these
terms were used. Two authors (APJJ, EJMND) indepen-
dently reviewed all included studies on title and abstract
and later on full text.
Inclusion criteria were all studies on resected pNET in
which the postoperative complications, in-hospital mor-
tality or survival after surgical resection was described.
Postoperative complications were defined as pancreatic
fistula, delayed gastric emptying, bleeding, and mortality as
in-hospital mortality after resection. Finally, at least 10
patients with a pNET had to be included in the study to
reduce bias and heterogeneity and to enhance scientific
relevance. Studies were scored as invalid if the patients
were analyzed as a part of a larger cohort of none-pNET
and the data of the patients with a pNET could not be
extracted from full-text analysis. Also, if not all described
patients had undergone surgery and/or the resected patients
have not been described separately or if studies described
the postoperative complications or in-hospital mortality of
the entire group and not specific after one surgical proce-
dure, studies were scored as invalid. Finally, in order to
improve homogeneity, studies were excluded from the
5-year survival analysis if all the patients of the study were
affected with the MEN-1-syndrome/VHL disease or if all
the included patients in the study had liver metastasis at
time of surgery.
Data collection and statistical analysis
After screening on title and abstract, a full-text screening
was performed to determine if the studies fulfilled the
inclusion criteria. Data of postoperative complications, in-
hospital mortality and survival were extracted. If possible,
the complications were scored according the ISGPF/S
criteria [15–17]. An overall (grade A/B/C) pancreatic fis-
tula rate and if possible a grade B/C pancreatic fistula rate
was calculated. If the grade B/C pancreatic fistula rate was
not described in detail, then that study was only included in
the overall pancreatic fistula proportion analysis. The same
yields for delayed gastric emptying and postoperative
hemorrhage. The variables of the postoperative complica-
tions and in-hospital mortality were analyzed for each
surgical procedure. Studies on survival were only included
if the overall 5-year survival and/or the 5-year disease-
specific survival after curative resection could be extracted
in patients with and/or without curative resected liver
metastases. No strict definitions of a curative resection
were enforced. If the survival was analyzed based on
resection margins, the R0 resection margin was used.
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Postoperative complications, in-hospital mortality and
5-year survival were given in proportions with a 95 %
confidence interval (CI) and a meta-analysis of these pro-
portions was performed with R [18]. The random effects
model was used for expected heterogeneity. The I2 statis-
tics was used to measure the consistency between the
studies in the meta-analysis. If the I2 statistics was above
75 %, the heterogeneity was considerable and the results of
proportion analysis were not suitable for a meta-analysis
[19–21]. In order to make a distinction in the quality of the
studies, prospective and retrospective studies were ana-
lyzed separately. From all the prospective and retrospective
studies an estimated pooled proportion was calculated and
if the I2 statistics were both below 75 %, all studies were
pooled in an overall proportion.
Assessment of risk of bias
For the assessment of the risk of bias, the methodological
index for non-randomized studies (MINORS) was used
[22]. The MINORS contains 8 items: clear stated aim,
inclusion consecutive patients, prospective data collection,
endpoints appropriate to aim, unbiased assessment of the
endpoint, appropriate follow-up period, loss to follow-up
\5 % and prospective calculation of study size. Based on
these eight items, the included studies will be scored to a
3-point scale from 0 to 2. An item scored 0 if the item was
not reported. An item scored 1, if it was reported but
inadequate and an item scored 2 if it was reported and
adequate. The ideal total score would be 16. An appropriate
follow-up for the studies included in the survival analysis
Fig. 1 Flow Chart of the search strategy
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was at least 40 months. If it was not exactly described
whether all the patients were included in the follow-up, the
study scored 1 point in ‘‘lost to follow-up’’.
Results
A total of 2643 studies were identified through searching
the different databases, including Cochrane Central
Register of Controlled trials (CENTRAL) in the Cochrane
Library, MEDLINE and EMBASE. A total of 511 dupli-
cate studies were excluded, as depicted in Fig. 1, therefore
2132 references were suitable for further assessment. Of all
these references, 1956 were excluded because they did not
meet the inclusion criteria or the studies were invalid.
Initially 176 studies were included in the full-text search
and after these articles looked through, 114 studies were
withdrawn by their outcome. Finally, 62 studies were
included in this meta-analysis, 10 studies for postoperative
complications, in-hospital mortality and survival analysis,
16 studies for only postoperative outcome analysis and 36
for only survival analysis, as depicted in Fig. 1.
Postoperative complications
Pancreatic fistula
Estimated pooled pancreatic fistula (PF) rate after tumor
enucleation was 45 % (95 % CI 34–57 %, I2 57 %), based
on 6 prospective studies with 220 included patients [23–
28]. Heterogeneity of the 16 retrospective studies was too
high to pool all 22 studies, as depicted in Fig. 2 [29–44].
Prospective studies
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Fig. 2 Overall pancreatic fistula rate after tumor enucleation
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Fig. 3 Overall pancreatic fistula rate after distal pancreatectomy
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Fig. 4 Overall pancreatic fistula rate after pancreatoduodenectomy
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Overall PF rate grade B/C after tumor enucleation was
27 % (95 % CI 19–37 %), based on 8 studies with a total
of 324 included patients [24, 25, 27, 28, 38, 40, 43] (see
appendix Fig. 13). Overall PF rate after distal pancreatec-
tomy was 14 % (95 % CI 10–19 %), based on 18 studies
with a total of 383 included patients, as depicted in Fig. 3
[23, 24, 29–37, 39, 41–44, 45, 46]. The overall grade B/C
PF rate after distal pancreatectomy was 8 % (95 % CI
2–35 %), based on 2 studies with a total of 74 included
patients [24, 43] (see appendix Fig. 14). Overall PF rate
after pancreatoduodenectomy was 14 % (95 % CI 9–21),
based on 11 studies with a total amount of 171 included
patients as depicted in Fig. 4 [23, 29–31, 34, 35, 41, 44,
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Fig. 5 Overall delayed gastric emptying rate after tumor enucleation
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Fig. 6 Overall delayed gastric emptying rate after distal pancreatectomy
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Fig. 7 Overall delayed gastric emptying rate after pancreatoduodenectomy
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in detail. Overall PF rate after central pancreatectomy was
58 % (95 % CI 41–73 %), based on four studies with a
total of 56 included patients (see appendix Fig. 15) [25, 28,
34, 41]. Two studies described grade B/C PF rate ranging
from 12 to 41 % (see appendix Fig. 16). Heterogeneity was
too high to perform a pooled meta-analysis (I2 77 %) [25,
28].
Delayed gastric emptying
Delayed gastric emptying (DGE) was rarely reported and
only the overall DGE rate was analyzed since none of the
included studies made a distinction based on the ISGPS
criteria. Overall DGE rate after tumor enucleation was 5 %
(95 % CI 2–10 %) based on six studies with a total amount
Prospective studies
Estimated pooled proportion
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Fig. 8 Overall postoperative hemorrhage rate after tumor enucleation
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Fig. 9 Overall postoperative hemorrhage rate after distal pancreatectomy
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Fig. 10 Overall postoperative hemorrhage rate after pancreatoduodenectomy
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of 231 included patients (see Fig. 5) [26, 28, 34, 35, 38,
46]. Overall DGE rate after distal pancreatectomy was 5 %
(95 % CI 1–19 %, I2 12 %) [34, 35, 46], based on three
studies with a total of 62 included patients (see Fig. 6),
after pancreatoduodenectomy 18 % (95 % CI 10–31 %, I2
0 %) [34, 35, 46] based on three studies with a total of 51
included patients (see Fig. 7) and after central pancreate-
ctomy, 16 % (95 % CI 1–71 %, I2 73 %) [28, 34] (see
appendix Fig. 17).
Postoperative hemorrhage
Postoperative hemorrhage was often not exactly defined
according the ISGPS criteria in most studies. Therefore, a
distinction between grade A and B/C hemorrhage could not
be made. Six studies described the overall postoperative
hemorrhage rate after tumor enucleation with a total
amount of 254 included patients (see Fig. 8). In these
studies, the overall postoperative hemorrhage rate was 6 %
(95 % CI 3–12 %) [25, 26, 28, 35, 39, 44]. Two studies
with a total amount of 62 included patients described an
overall postoperative hemorrhage rate of 1 % after distal
pancreatectomy (95 % CI 0–9 %, I2 0 %) [35, 44] as
depicted in Fig. 9. Overall postoperative hemorrhage rate
after pancreatoduodenectomy was 7 % (95 % CI 3–15 %,
I2 0 %), based on four studies with a total of 77 included
patients [35, 44, 47, 48] (see Fig. 10) and after central
pancreatectomy 4 % (95 % CI 1–16 %, I2 0 %), based on 2
studies (see appendix Fig. 18) [25, 28].
In-hospital mortality
Overall pooled in-hospital mortality rate after tumor enu-
cleation was 3 % (95 % CI 2–5 %), based on 20 studies
with a total amount of 624 patients [23–25, 28–40, 42, 44,
46] (see appendix Fig. 19). The overall pooled in-hospital
mortality after distal pancreatectomy was 4 % (95 % CI
2–7 %) [23, 24, 29–37, 39, 42, 44, 45, 46], based on 16
studies with a total of 267 included patients (see appendix
Fig. 20) and 6 % after pancreatoduodenectomy (95 % CI
3–12 %), based on 10 studies with a total of 146 included
patients [23, 29–31, 34, 35, 44, 46–48] (see appendix
Fig. 21). The overall pooled in-hospital mortality after
central pancreatectomy was 4 % (95 % CI 1–16 %), based
on 3 studies with a total of 51 included patients (see
appendix Fig. 22) [25, 28, 34].
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Fig. 11 Overall 5-year survival in patients without liver metastases.
1 High grade: patients with grade 3 or poorly differentiated pNET
may be included. 2 MEN: patients with a hereditary syndrome such
as MEN1 syndrome or von Hippel Lindau may be included. 3 NF/F.
Patients with non-functional pNET or functional pNET may be
included. ? Some patients are affected with the condition. - None of
the patients are affected with the condition. NS not specified. The
study did not specified the number of patients with the condition
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Survival analysis
The 5-year overall and disease-specific survival in patients
without liver metastases
In the survival analysis, a distinction is made between
studies including patients with or without resected liver
metastases. In the overall 5-year survival analysis of the
resected patients without liver metastases, 15 studies were
analyzed with a total of 3089 included patients [28, 36,
38, 41, 49–59]. The heterogeneity between the prospec-
tive studies was too high to perform a pooled meta-
analysis (I2 95 %), mainly caused by the study of Bil-
imoria et al. [59]. The estimated pooled proportion of the
overall 5-year survival of the retrospective studies was
85 % (95 % CI 78–90 %, I2 73.5 %), see Fig. 11. In the
5-year disease-specific survival (DSS) analysis, 6 studies
were included with a total amount of 420 patients [43, 50,
52, 60–62]. The overall pooled 5-year DSS after pancre-
atic resection was 93 % (95 % CI 88–96 %), see appen-
dix Fig. 23.
The 5-year overall and disease-specific survival in patients
with liver metastases
In all the included studies, at least one patient per study had
resected liver metastases. In the 5-year overall survival
analysis, 23 studies were included with a total amount of
1540 patients [23, 35, 44, 46, 48, 63–80]. The hetero-
geneity was too high to perform an overall pooled pro-
portion analysis, most studies included a proportion of high
grade pNET (see Fig. 12). Four retrospective studies with a
total of 207 included patients described the 5-year disease-
specific survival in patients with liver involvement. The
overall pooled 5-year DSS was 80 % (95 CI 66–90 %, I2
70 %), see appendix Fig. 24 [81–84].
Retrospective studies
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Fig. 12 Overall 5-year survival in patients with liver metastases. 1
High grade: patients with grade 3 or poorly differentiated pNET may
be included. 2 MEN: patients with a hereditary syndrome such as
MEN1 syndrome or von Hippel Lindau may be included. 3 NF/F.
Patients with non-functional pNET or functional pNET may be
included. ? Some patients are affected with the condition. - None of
the patients are affected with the condition. NS not specified. The
study did not specified the number of patients with the condition
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Assessment of risk of bias
On overview of the risk of bias of all the included studies is
listed in Table 1. The variety of the total points ranged
from 5 to 12 points. None of the studies scored on unbiased
assessment of the study endpoint or prospective calculation
of the study size. Overall, 33/62 studies (53 %) had a high
MINOR score of C10 and only 8 studies (13 %) had a low
MINOR score B7.
Discussion
This is the first systematic review including a proportion
analysis on postoperative complications, in-hospital mortality
and 5-year survival in patients with a pancreatic neuroen-
docrine tumor. Pooled PF rate after tumor enucleation of the
prospective studies was high (45 %) compared to overall
pooled PF rate after distal pancreatectomy (14 %) and pan-
creatoduodenectomy (14 %). In patients with other diagnosis
including pancreatic adenocarcinoma, the overall incidence of
PF after pancreatoduodenectomy ranges from 2 % up to more
than 20 % [85–88] and after distal pancreatectomy from
12–32 % [89–93] and the overall PF rate in non-pNET diag-
nosis is between 11 and 17 % compared to 6–34 % in patients
with pNET [40, 45, 94–96]. This is coherent with the inci-
dence of PF in patients with pNET in our review. Since the
presence of PF accounts in the majority of cases for a pro-
longed hospital stay, the high incidence of these complications
after tumor enucleation is alarming. Also the incidence of
delayed gastric emptying (18 %) in patients with pNET after
pancreatoduodenectomy in our review is comparable with the
overall incidence from 14 to 45 % after pancreatoduodenec-
tomy in patients with non-pNET [97–99].
The overall mortality in patients with pNET in our review is
between 3 and 6 %. In the literature the recent overall mor-
tality in non-pNET is between 0 and 4 % [91, 96, 100–102].
The overall in-hospital mortality rate in our review is slightly
high. This is probably due to the fact that we included studies
already from the year 2000 and centralization of pancreatic
surgery takes place only since the last few years. The in-
hospital mortality rate after pancreatoduodenectomy has been
decreased from 15 % to even 1 or 2 % in high volume centers
[103–105]. Therefore, the effect of centralization on in-hos-
pital mortality is not shown in our review. Furthermore, in
some studies on patients with pNET, pancreatic resection was
not specified in pancreatoduodenectomy of distal pancreate-
ctomy. In the analysis of the in-hospital mortality, these
studies were excluded [10, 28, 40]. A second important point
could be the texture of the pancreatic remnant after resec-
tion. In patients with pNET, especially small pNETs, there is
no pancreatic duct dilation, no fibrosis and the pancreatic
remnant is soft and viable. This is in contrast with most
patients with non-pNET tumors with have a double duct sign
and subsequent fibrosis of the pancreatic remnant. Since the
texture of the pancreatic remnant is well known to be asso-
ciated with PF and mortality this could a reasonable expla-
nation [5, 106, 107]. Unfortunately, in this review, we could
not find data on this important detail to draw conclusions
concerning this point.
The analysis of postoperative complications in pancreatic
surgery is more uniform since the clear definitions of these
complications by the International Study Group of Pancreatic
Surgery (ISGPS) [15–17]. The number of studies suitable for
inclusion in the proportion analysis for pancreatic fistula grade
B/C was limited. Most studies on grade B/C fistula (or delayed
gastric emptying and postoperative hemorrhage) included
patients with different underlying diseases. Patients with
pNET were part of the studied cohort. These studies were not
included in this review. Tumor enucleation is mainly indicated
for pNET and therefore the number of studies for proportion
analysis on grade B/C pancreatic fistula was relatively high
compared to the other procedures (appendix Fig. 13). In future
studies, we encourage the use of the ISGPS criteria in the
analysis of postoperative complications and to describe the
patients with pNET separately.
Recently, Hu¨ttner et al. described a high incidence of
pancreatic fistula after tumor enucleation in patients with all
types of pancreatic neoplasm [108]. Although the authors
conclude that a tumor enucleation can be performed safely and
is considerable instead of a standard resection, this conclusion
should be interpreted with caution. Even in high volume
centers, the incidence of pancreatic fistula was comparable
after both tumor enucleation and standard resection (both
23 %). Although overall length of stay and mortality after
tumor enucleation is lower compared to standard resection,
patients with severe pancreatic fistula will have comparable
length of stay and mortality. Since specialized care for patients
with PF is important for overall outcome, enucleations should
also be carried out in specialized centers.
A considerable amount of studies described the 5-year
survival after pancreatic resection with or without liver
metastases. The 5-year disease-specific survival in patients
with and without liver metastases was fairly comparable with,
respectively, 93 and 80 %. Although there will be differences
in tumor differentiation, functionality, or hereditary tumors,
the survival rate after surgical resection in patients with liver
metastases is high. An aggressive treatment in patients with
liver metastases may be justified. However, both patients and
tumor characteristics, such as total tumor load in the liver, are
important in this treatment. In our review, the heterogeneity
between the included studies in the 5-year overall survival
analysis was high (Figs. 9 and 10). These differences can be
explained by the patients’ characteristics of the included
studies. For example, in the study of Bahra et al., patients were
enrolled with at least two malignant factors such as invasion in
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adjacent organs, metastases, tumor invasion, tumor size
C2 cm, and tumor grade 2 or 3 pNET [71]. Bilimoria et al. [59]
also enrolled patients with distant metastases (20 %), positive
lymph nodes (52.8 %), and poorly differentiated pNET
(22.1 %). Most likely, a high grade/poorly differentiated tumor
has more influence on survival than the presence of resected
liver metastases. This hypothesis has not been analyzed in this
review. In addition, in most studies no differentiation was
made between functional and non-functional pNET.
Since no randomized controlled trials were available,
heterogeneity was notable. During full-text analysis, some
studies were not clear or incomplete on the description of the
outcome. For example, studies described the postoperative
after ‘‘standard pancreatic resection’’ but different definitions
for a standard resection were used. Some studies described
patients after pancreatoduodenectomy and distal pancreatec-
tomy [10, 28, 108] while other studies described patients with
all types of pancreatic resection including central pancreate-
ctomy and total pancreatectomy [26, 38, 40]. Furthermore,
some large studies, especially studies that extracted the data
from the SEER database, described the survival outcome per
tumor stage and most of these studies have not described an
overall 5-year survival. Moreover, it was not always clear if all
the included patients with stage IV disease were operated. All
these studies were excluded from this review. There is no
agreement of the exact cut-off value of heterogeneity in which
it is accepted to perform a meta-analysis. According to the
Cochrane handbook, with an I2 above 75, heterogeneity is
considerable [21]. By the strict inclusion criteria, effort has
been made to include homogeneous data and studies with
good quality but the diversity of the studies on pNET is
considerable and this review shows the best available data up
till now.
Conclusion
Based on this review, we would like to recommend using
uniform definitions for ‘‘pancreatic resection’’ or well-de-
scribed ‘‘atypical resections’’ for a careful comparison of
clinical outcome. Furthermore, the ISGPS criteria and Cla-
vien–Dindo grading system should be used in the analysis of
postoperative complications. In survival analysis, distin-
guishes should be made between tumor grade/tumor differ-
entiation, patients with a hereditarily syndrome and patients
with a functional or non-functional pNET. Although pNET is
a rare disease, studies on postoperative outcome and survival
must be uniform and clear to be able to interpret the results in
the right way and to use the results in daily practice.
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Fig. 13 Pancreatic fistula rate grade B/C after tumor enucleation
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Fig. 19 In-hospital mortality rate after tumor enucleation
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Fig. 23 5-year disease-specific survival in patients without liver
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tiated pNET may be included. 2 MEN: patients with a hereditary
syndrome such as MEN1 syndrome or von Hippel Lindau may be
included. 3 NF/F. Patients with non-functional pNET or functional
pNET may be included. ? Some patients are affected with the
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